- Stocks
- Pharma & Healthcare
- Parmax Pharma
Parmax Pharma share price
NSE: PARMAXPharma & HealthcareDrug Manufacturers - Specialty & Generic
Parmax Pharma at a glance
With a market capitalisation of ₹25 Cr, it ranks 3463rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 0.0% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹3 Cr (−31.5% year on year) and net profit −₹1 Cr, on a standalone basis. Promoters held 30.80% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹25 CrRank 3463 on NSE
- Price to book
- -9.46×FY25
- EPS (TTM)
- −₹11.12to Q4 FY26
- ROE
- 0.0%FY25
- ROCE
- −12.9%FY25
- Debt to equity
- -3.87FY25
- Net profit margin
- −7.4%FY25
- Book value / share
- −₹4.47FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Parmax Pharma quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹8 Cr | ₹9 Cr | ₹6 Cr | ₹5 Cr | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr |
| Revenue YoY | +458.6% | +128.0% | +372.2% | +13.4% | −75.2% | −72.7% | −31.1% | −31.5% |
| Net profit | ₹0 Cr | −₹0 Cr | −₹0 Cr | −₹1 Cr | −₹1 Cr | −₹2 Cr | −₹1 Cr | −₹1 Cr |
| Net profit YoY | — | — | — | — | −7,700.0% | — | — | — |
| Net margin | 0.1% | −2.4% | −6.2% | −30.8% | −39.2% | −82.2% | −16.9% | −17.5% |
| EPS | ₹0.03 | −₹0.58 | −₹1.05 | −₹4.00 | −₹2.04 | −₹5.56 | −₹1.96 | −₹1.56 |
Parmax Pharma financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹21 Cr | ₹26 Cr | ₹18 Cr | ₹15 Cr | ₹11 Cr | ₹28 Cr |
| Operating profit | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | −₹6 Cr | −₹1 Cr |
| Net profit | ₹0 Cr | ₹1 Cr | ₹0 Cr | −₹0 Cr | −₹6 Cr | −₹2 Cr |
| EPS (₹) | ₹1.15 | ₹2.02 | ₹0.38 | −₹0.28 | −₹11.33 | −₹5.60 |
| Cash from operations | ₹3 Cr | ₹4 Cr | ₹1 Cr | ₹0 Cr | −₹0 Cr | −₹1 Cr |
| Total debt | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹6 Cr | ₹8 Cr |
| Shareholders' equity | ₹5 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹0 Cr | −₹2 Cr |
Parmax Pharma shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 30.80% | 30.80% | 30.80% | 30.80% | 30.80% | 30.80% |
| Non-institutions | 69.20% | 69.20% | 69.20% | 69.20% | 69.20% | 69.20% |
Parmax Pharma vs peers
The listed Pharma & Healthcare companies nearest to Parmax Pharma by market capitalisation.
Ask anything about Parmax Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against PARMAX's own history. Try: “Why has PARMAX moved over the last three months?” · “Backtest a 50-day moving-average crossover on PARMAX over five years” · “Compare PARMAX with CMMHOSP on margins and valuation”
Frequently asked questions about Parmax Pharma
What is the market cap of Parmax Pharma?
Parmax Pharma's market capitalisation is ₹25 Cr (₹25 Cr) at the 22 Oct 2026 close, ranking 3463rd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Parmax Pharma?
Return on equity was 0.0% in FY25 and return on capital employed was −12.9% in FY25 (standalone figures).
Is Parmax Pharma a debt-free company?
Parmax Pharma is close to debt-free: its debt-to-equity ratio was -3.87 in FY25.
What were Parmax Pharma's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Parmax Pharma reported revenue of ₹3 Cr, −31.5% year on year, and net profit of −₹1 Cr.
What is the shareholding pattern of Parmax Pharma?
As of 30 Jun 2026: promoters 30.80%, non-institutions 69.20%.
Who are Parmax Pharma's competitors?
The listed Pharma & Healthcare companies closest to Parmax Pharma by market cap are Chennai Meenaks, Tejnaksh, SAMSRITA LABS, SUPHA PHARMACHE, Transgene Biote and Hamps Bio.
Is Parmax Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Parmax Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on PARMAX against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with P · all NSE stocks · this page as text